Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for asthma
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Asthma in adults and adolescents: what’s new for mild asthma management? Asthma in adults and adolescents: what’s new for mild asthma management? - NPS MedicineWise Log In Menu During the COVID-19 pandemic, you need to continue to take your usual medicines and stay as healthy as possible. Health professionals also need to stay up to date with the latest evidence as it emerges. Our information hub has important information for everyone. Featured topics 02 Sep 2020 06 Aug 2020 03 Aug 2020 24 Jun (...) in Log in All fields are required Email address* Password* Log in Rate us How likely is it that you would recommend our site to a friend? Please help us to improve our services by answering the following question How likely is it that you would recommend our site to a friend? 0 1 2 3 4 5 6 7 8 9 10 0 = Not likely at all 10 = Extremely likely Please feel free to tell us why SUBMIT Asthma in adults and adolescents: what’s new for mild asthma management? A new approach offers an alternative to low-dose
Asthma – optimising long-term management with inhaled corticosteroid Optimising long-term management with inhaled corticosteroid Asthma Academy of Medicine, Singapore Chapter of Fam ily Medicine Physicians Chapter of General Physicians Chapter of Respiratory Physicians College of Emergency Physicians College of Paediatrics and Child Health College of Family Physicians Singapore Target audience This clinical guidance is relevant to all healthcare professionals caring for patients with asthma (...) , especially those in primary care Objective To advance appropriate management of asthma Scope Clinical assessment, pharmacological treatment, and non-pharmacological strategies for managing asthma over the long term Published: 15 October 2020 www.ace-hta.gov.sg ACE CLINICAL GUIDANCE Asthma is one of the most common chronic respiratory conditions seen in primary care in Singapore. 1 Around 5% of residents in Singapore aged 18 to 69 years have asthma. 2 About 1 in 3 patients with asthma aged 12 years
Indacaterol acetate/mometasone furoate (Atectura Breezhaler) for the maintenance treatment for asthma in adults and adolescents of 12 years and older Indacaterol acetate/mometasone furoate (Atectura® Breezhaler®) for the maintenance treatment for asthma in adults and adolescents of 12 years and older | Report | National Health Care Institute You are here: Indacaterol acetate/mometasone furoate (Atectura® Breezhaler®) for the maintenance treatment for asthma in adults and adolescents of 12 years (...) and older Search within English part of National Health Care Institute Search Indacaterol acetate/mometasone furoate (Atectura® Breezhaler®) for the maintenance treatment for asthma in adults and adolescents of 12 years and older Zorginstituut Nederland has completed its assessment whether indacaterol acetate/mometasone furoate (Atectura® Breezhaler®) can be included in the Medication Reimbursement System (GVS). The Zorginstituut's advice is to include Atectura® Breezhaler® in List 1B of the GVS
Indacaterol/glycopyrronium/mometasone (Enerzair Breezhaler) for maintenance treatment of asthma in adult patients Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients | Report | National Health Care Institute You are here: Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients Search within English part of National Health Care Institute Search Indacaterol/glycopyrronium (...) /mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients Zorginstituut Nederland has completed its assessment whether indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients can be included in the Medication Reimbursement System (GVS). The Zorginstituut's advice is to include Enerzair® Breezhaler® in List 1B of the GVS on technical grounds. Active ingredients of Enerzair® Breezhaler® already included in the GVS
Sublingual immunotherapy for asthma. Asthma is a common long-term respiratory disease affecting approximately 300 million people worldwide. Approximately half of people with asthma have an important allergic component to their disease, which may provide an opportunity for targeted treatment. Sublingual immunotherapy (SLIT) aims to reduce asthma symptoms by delivering increasing doses of an allergen (e.g. house dust mite, pollen extract) under the tongue to induce immune tolerance. Fifty-two (...) articles found trials up to 25 March 2015. The most recent search for trials for the current update was conducted on 29 October 2019.We included parallel randomised controlled trials, irrespective of blinding or duration, that evaluated sublingual immunotherapy versus placebo or as an add-on to standard asthma management. We included both adults and children with asthma of any severity and with any allergen-sensitisation pattern. We included studies that recruited participants with asthma, rhinitis
Benralizumab, mepolizumab and omalizumab for treating severe asthma 1 Driving better decision-making in healthcare Benralizumab, mepolizumab and omalizumab for treating severe asthma Technology Guidance from the MOH Drug Advisory Committee Published on 1 September 2020 Guidance recommendations The Ministry of Health’s Drug Advisory Committee has not recommended listing: • Benralizumab and mepolizumab on the Medication Assistance Fund (MAF) for treating severe eosinophilic asthma (...) ; and • Omalizumab on the MAF for treating severe allergic asthma due to unacceptable cost-effectiveness at the prices proposed by the manufacturers. 2 Driving better decision-making in healthcare Factors considered to inform the recommendations for subsidy Technology evaluation 1.1 1.2 1.3 1.4 The MOH Drug Advisory Committee (“the Committee”) considered the evidence presented for the following technology evaluations in October 2019: a) Benralizumab for treating adults and mepolizumab for treating adults
Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial. Severe asthma exacerbations cause significant morbidity and costs. Whether vitamin D3 supplementation reduces severe childhood asthma exacerbations is unclear.To determine whether vitamin D3 supplementation improves the time to a severe exacerbation in children with asthma and low vitamin D levels.The Vitamin D to Prevent Severe Asthma (...) Exacerbations (VDKA) Study was a randomized, double-blind, placebo-controlled clinical trial of vitamin D3 supplementation to improve the time to severe exacerbations in high-risk children with asthma aged 6 to 16 years taking low-dose inhaled corticosteroids and with serum 25-hydroxyvitamin D levels less than 30 ng/mL. Participants were recruited from 7 US centers. Enrollment started in February 2016, with a goal of 400 participants; the trial was terminated early (March 2019) due to futility, and follow
Air pollution and family related determinants of asthma onset and persistent wheezing in children: nationwide case-control study. To identify risk factors (air pollution and family related) for the onset of asthma and persistent wheezing in children.Nationwide case-control study.Denmark.All Danish children born from 1997 to 2014 and followed for asthma onset and persistent wheezing from age 1 year to 15 years.Onset of asthma and persistent wheezing.A higher incidence of asthma was found (...) in children of parents with asthma (adjusted hazard ratio 2.29 (95% confidence interval 2.22 to 2.35) and mothers who smoked during pregnancy (1.20, 1.18 to 1.22), whereas a lower incidence was found in children of parents with high educational attainment (0.72, 0.69 to 0.75) and high incomes (0.85, 0.81 to 0.89). Exposure to particulate matter ≤2.5 µm (PM2.5) and ≤10 µm (PM10) and nitrate was associated with an increased risk of asthma and persistent wheezing, with hazard ratios per 5 µg/m3 increase
Self-management interventions to reduce healthcare use and improve quality of life among patients with asthma: systematic review and network meta-analysis. To compare the different self-management models (multidisciplinary case management, regularly supported self-management, and minimally supported self-management) and self-monitoring models against usual care and education to determine which are most effective at reducing healthcare use and improving quality of life in asthma.Systematic (...) review and network meta-analysis.Medline, the Cochrane Library, CINAHL, EconLit, Embase, Health Economics Evaluations Database, NHS Economic Evaluation Database, PsycINFO, and ClinicalTrials.gov from January 2000 to April 2019.Randomised controlled trials involving the different self-management models for asthma were included. The primary outcomes were healthcare use (hospital admission or emergency visit) and quality of life. Summary standardised mean differences (SMDs) and 95% credible intervals
Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews. Asthma is an illness that commonly affects adults and children, and it serves as a common reason for children to attend emergency departments. An asthma exacerbation is characterised by acute or subacute worsening of shortness of breath, cough, wheezing, and chest tightness and may be triggered by viral respiratory infection, poor compliance with usual medication, a change (...) in the weather, or exposure to allergens or irritants. Most children with asthma have mild or moderate exacerbations and respond well to first-line therapy (inhaled short-acting beta-agonists and systemic corticosteroids). However, the best treatment for the small proportion of seriously ill children who do not respond to first-line therapy is not well understood. Currently, a large number of treatment options are available and there is wide variation in management.Main objective - To summarise Cochrane
Management of Severe Asthma Management of Severe Asthma: a European Respiratory Society/American Thoracic Society Guideline | European Respiratory Society Main menu User menu Search Search for this keyword Search for this keyword Management of Severe Asthma: a European Respiratory Society/American Thoracic Society Guideline Fernando Holguin , Juan Carlos Cardet , Kian Fan Chung , Sarah Diver , Diogenes S. Ferreira , Anne Fitzpatrick , Mina Gaga , Liz Kellermeyer , Sandhya Khurana , Shandra (...) Parana, Curitiba, Brazil 6 School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia Anne Fitzpatrick 7 Emory University, Division of Pulmonology Allergy/Immunology, Cystic Fibrosis and Sleep, Atlanta, GA, USA Mina Gaga 8 Athens Chest Hospital, Respiratory Medicine Department and Asthma Centre, Athens, Greece Liz Kellermeyer 9 Biomedical Library, National Jewish Health, Denver, CO, USA Sandhya Khurana 10 Pulmonary Diseases and Critical Care, University of Rochester
Statins for asthma. Asthma is a common chronic respiratory disease. People with asthma have inflammation of their airways that causes recurrent episodes of wheezing, breathlessness and chest tightness, with or without a cough. Statins possess multiple therapeutic effects, including lowering lipid levels in the blood. Statins are reported to have a potential role as an adjunct treatment in asthma. However, comprehensive evidence of the benefits and harms of using statins is required (...) to facilitate decision making.To assess the benefits and harms of statins as an adjunct therapy for asthma in adults and children.We searched for studies in the Cochrane Airways Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Ovid SP and Embase Ovid SP, from their inception dates We handsearched the proceedings of major respiratory conferences. We also searched clinical trials registries for completed, ongoing and unpublished studies, and scanned the reference lists
Travel for people with allergy, asthma and anaphylaxis ASCIA Travel Plan: Anaphylaxis - Australasian Society of Clinical Immunology and Allergy (ASCIA) | | ASCIA Travel Plan: Anaphylaxis Other travel information for people at risk of anaphylaxis is available from Allergy & Anaphylaxis Australia: Page updated January 2019 Site last updated: 6 Nov 2019 Member Login Remember Me Log in ASCIA Update Information for the community about allergic diseases, immunodeficiencies and other immune diseases
Inhaled Salbutamol Shortage – Mitigation Strategy for Asthma CTS Guidance on Salbutamol Shortage – April 13,2020 1 Inhaled Salbutamol Shortage – Mitigation Strategy for Asthma April 13, 2020 Background 1) Health Canada and the pharmaceutical industry have identified that there was a three-fold increase in the demand for salbutamol inhalers in the first 3 weeks of March 2020. 2) This has resulted in a Tier 3 shortage, which by definition is “a situation when a manufacturer/importer is unable (...) and organizations projecting future need and purchasing product in advance of actual need [Stockpiling]. Mitigation Strategy Step 1 Provider communication to patients regarding asthma medication: If you have well controlled asthma, you should not need reliever medication. If you need reliever medication more than three times a week you should speak to your practitioner about ways to improve your asthma control. It is important that you are taking your regular maintenance controller medication as prescribed
Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guideline and Expert Panel Report Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents CHEST Guideline and Expert Panel Report AndreanneCôté,MD;RichardJ.Russell,MBBS;Louis-PhilippeBoulet,MD;PeterG.Gibson,DMed;KefangLai,MD,PhD; Richard S. Irwin, MD, Master FCCP; and Christopher E. Brightling, PhD; on behalf of the CHEST Expert Cough Panel * BACKGROUND: Asthma and non-asthmatic eosinophilic (...) and areas for future research. CHEST 2020; 158(1):68-96 KEYWORDS: asthma; bronchitis; cough ABBREVIATIONS: FENO= fractionalexhalednitric oxide;NAEB =non- asthmatic eosinophilic bronchitis; RCT = randomized controlled trial AFFILIATIONS: From the Centre de pneumologie (Drs Côté and Boulet), Québec Heart and Lung Institute, Laval University, Québec City, QC, Canada; Department of Respiratory Sciences (Drs Russell and Brightling), Institute for Lung Health, Glen?eld Hospital, Uni- versity of Leicester
Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the Covid-19 pandemic 1 ‘In Press’. Submitted for publication in the CJRCCSM on April 7, 2020. POSITION STATEMENT FROM THE CANADIAN THORACIC SOCIETY (CTS) ASTHMA ASSEMBLY STEERING COMMITTEE ADDRESSING THERAPEUTIC QUESTIONS TO HELP CANADIAN PHYSICIANS OPTIMIZE ASTHMA MANAGEMENT FOR THEIR PATIENTS DURING THE COVID-19 PANDEMIC Christopher Licskai a , Connie L. Yang b , Francine M (...) et de Pneumologie de Québec, Laval University, Québec, Québec, Canada; i Deparment of Medicine, Royal Victoria Regional Health Centre, Barrie, Ontario, Canada; j Department of Medicine, Queen’s University, Kingston, Ontario, Canada. Version 1.0 – April 7, 2020 This position statement aims to provide rapid guidance for Canadian physicians treating patients with asthma during the COVID-19 pandemic. The recommendations are informed by a very limited body of direct published data, inference from